Azzad Asset Management Inc. ADV bought a new position in shares of Natera, Inc. (NASDAQ:NTRA – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 3,949 shares of the medical research company’s stock, valued at approximately $905,000.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Horizon Investments LLC acquired a new position in Natera during the 3rd quarter worth $32,000. Sound Income Strategies LLC grew its stake in Natera by 95.7% during the 3rd quarter. Sound Income Strategies LLC now owns 225 shares of the medical research company’s stock worth $39,000 after purchasing an additional 110 shares in the last quarter. Flagship Harbor Advisors LLC acquired a new position in Natera during the 4th quarter worth $41,000. Quent Capital LLC acquired a new position in Natera during the 3rd quarter worth $46,000. Finally, Hilltop National Bank grew its stake in Natera by 59.8% during the 3rd quarter. Hilltop National Bank now owns 310 shares of the medical research company’s stock worth $50,000 after purchasing an additional 116 shares in the last quarter. 99.90% of the stock is owned by institutional investors and hedge funds.
Natera Price Performance
Natera stock opened at $209.27 on Wednesday. Natera, Inc. has a 1-year low of $130.29 and a 1-year high of $256.36. The stock has a market cap of $29.66 billion, a PE ratio of -136.78 and a beta of 1.68. The stock’s fifty day moving average is $205.91 and its two-hundred day moving average is $210.02.
Natera (NASDAQ:NTRA – Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The medical research company reported $0.35 EPS for the quarter, beating the consensus estimate of ($0.46) by $0.81. The company had revenue of $665.50 million for the quarter, compared to analyst estimates of $600.68 million. Natera had a negative net margin of 9.03% and a negative return on equity of 15.28%. During the same period in the prior year, the firm posted ($0.41) earnings per share. On average, research analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.
Insider Activity at Natera
In other Natera news, CEO Steven Leonard Chapman sold 85,299 shares of the stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $230.72, for a total value of $19,680,185.28. Following the transaction, the chief executive officer directly owned 127,881 shares in the company, valued at $29,504,704.32. This represents a 40.01% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider John Fesko sold 17,806 shares of the company’s stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $234.74, for a total transaction of $4,179,780.44. Following the completion of the transaction, the insider owned 177,591 shares of the company’s stock, valued at $41,687,711.34. This represents a 9.11% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 314,545 shares of company stock valued at $73,141,185. Company insiders own 5.63% of the company’s stock.
Analyst Ratings Changes
A number of research analysts recently issued reports on NTRA shares. Barclays lifted their price target on shares of Natera from $230.00 to $270.00 and gave the stock an “overweight” rating in a research note on Monday, December 15th. Morgan Stanley decreased their price target on shares of Natera from $265.00 to $250.00 and set an “overweight” rating for the company in a research note on Tuesday, March 3rd. Guggenheim lifted their price target on shares of Natera from $230.00 to $270.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. Wells Fargo & Company lifted their price target on shares of Natera from $205.00 to $215.00 and gave the stock an “equal weight” rating in a research note on Friday, February 27th. Finally, Zacks Research upgraded shares of Natera from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $253.47.
Read Our Latest Research Report on Natera
About Natera
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
Featured Stories
Receive News & Ratings for Natera Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Natera and related companies with MarketBeat.com’s FREE daily email newsletter.
